
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 18, 2015**

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

000-21846

(Commission File Number)

13-3632859

(I.R.S. Employer Identification No.)

9635 Granite Ridge Drive, Suite 100

San Diego, California

(Address of principal executive offices)

92123

(Zip Code)

Registrant's telephone number, including area code: **(858) 459-7800**

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure

The Registrant disclosed that on Thursday, June 18, 2015, it made a 13 minute presentation at the Bio International Convention in Philadelphia, Pennsylvania. A copy of the industry presentation materials are being furnished as an exhibit to this report and are incorporated by reference into this Item 7.01. Also, the Registrant posted the investor presentation materials to its website (www.aethlonmedical.com) today, June 18, 2015.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is being furnished pursuant to Item 7.01 above.

Exhibit No.	Description
99.1	Aethlon – Bio International Convention – 06-18-15

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.
(Registrant)

Date: June 18, 2015

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation Materials

FORWARD LOOKING STATEMENTS

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon ADAPT™ system, the Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com



Aethlon Medical, Inc.

BIO INTERNATIONAL CONVENTION
JUNE 18TH, 2015

JIM JOYCE
CHAIRMAN, CEO



THERAPEUTIC BIOFILTRATION DEVICES TO ADDRESS LIFE-THREATENING DISEASES



SAVE LIVES



Aethlon Highlights

- Expansive Therapeutic Platform
 - Lead product provides clinical pathway to address cancer and infectious viral pathogens
- DOD Government Contractor (DARPA)
 - Dialysis-like therapeutics program to treat sepsis




The Aethlon Hemopurifier®



Single-Use Removal of Viral Pathogens from Circulation





BROAD-SPECTRUM TREATMENT EXPERIENCE





Top 25 Best Inventions of 2014





The 11 Most Remarkable Advances in Healthcare in 2014



The Aethlon Hemopurifier®



Single-Use Removal of Viral Pathogens from Circulation



Rethinking the Treatment of Viral Pathogens

- **Rapid virus elimination**
 - Prior to cell and organ infection
- **Targets viral structure vs. inhibiting replication**
 - Allows broad-spectrum virus capture
- **Addresses virally shed glycoproteins**
 - To augment and preserve host immune response





DEPLOYED WITHIN THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT MACHINES



Recent Clinical Advancements

- Disclosure of HCV treatment results
- Reported the treatment of Ebola patient
- First clinical protocols approved by FDA
 - Initiated IDE Feasibility Study in HCV Patients
 - Ebola Treatment Protocol
- Health Canada clinical approval (Ebola)



Ebola Virus as a Therapeutic Model



Reported Ebola Treatment Results

Frankfurt University Hospital



Special approval from The Federal Institute for Drugs and Medical Devices (BfArM)





Hemopurifier® therapy
administration to a
comatose Ebola patient
with multiple-organ failure



Ebola Treatment Data

Presented By Dr. Helmut Geiger
American Society of Nephrology Annual Meeting

- 6.5 hour Hemopurifier® therapy administration
- Pre-treatment viral load: 400,000 copies/ml
- Post-treatment viral load: 1,000 copies/ml
- 242 million of Ebola viruses captured
- Patient recovered and returned home





Dr. Stefan Büttner
Holding Hemopurifier®
After Ebola Treatment



Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease – First Experience with Lectin Affinity Plasmapheresis


- Stefan Büttner^a Benjamin Koch^a Olga Dolnik^b Markus Eickmann^b Tilo Freiwald^a Sarah Rudolf^a Jürgen Engel^a Stephan Becker^b Claudio Ronco^c Helmut Geiger^a
- ^a Medical Clinic III, Department of Nephrology, University Hospital Frankfurt, Frankfurt am Main, and ^b Institute of Virology, Philipps University Marburg, Marburg, Germany; ^c Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy
- Published: February 11, 2015



Unmet Needs in Infectious Disease

- Antiviral Drug-Resistance
 - HIV & HCV
- Latent Virus Activation
 - Immune Suppression
 - HIV, Organ Transplants, Sepsis
- Bioterror & Pandemic Threats
 - Leading broad-spectrum countermeasure against known and unknown viruses





ONE MORE THING



The Aethlon Hemopurifier®



SAVE LIVES




CANCER



Tumor-Secreted Exosomes

Extracellular Vesicles or Circulating Microvesicles



May, 2014
Trends in Molecular Medicine
*"Extracellular Vesicles: Emerging
Targets for Cancer Therapy"*



Tumor-Secreted Exosomes

A Significant Unmet Medical Need in Cancer

- Trigger apoptosis of immune cells
- Contribute to drug and chemotherapy resistance
- Promote angiogenesis
- Seed the creation and spread of metastasis
- Exosome load correlates with stage of cancer
- Transport PD-1, PDL-1 other immuno-oncology targets



An Adjunct Immunotherapeutic Device



Selected Clinical & Corporate Goals

- Complete FDA Approved IDE Study
 - Prep for pivotal study
- Advance HUD submissions
 - Disease conditions affecting < 4000 per yr. in the U.S.
- Complete NASDAQ Up-listing
- Launch Immuno-Oncology Programs



THERAPEUTIC BIOFILTRATION DEVICES TO ADDRESS LIFE-THREATENING DISEASES



SAVE LIVES



